All AbMole products are for research use only, cannot be used for human consumption.
In vitro: In bone marrow-derived macrophages (BMDMs), Sotuletinib (BLZ945) specifically inhibits CSF-1-dependent proliferation with EC50 of 67nM, and decreases CSF-1R phosphorylation. Sotuletinib (BLZ945) blocks the reciprocal effects between macrophages and glioma cells on the survival, proliferation and/ or polarization of each other to promote tumorigenesis.
In vivo: In glioma-bearing mice, BLZ945 blocks tumor progression and significantly improves survival via CSF-1R inhibition. Sotuletinib (BLZ945) also inhibits orthotopic tumor growth of patient-derived proneural tumor spheres and cell lines in vivo. Sotuletinib (BLZ945) (200 mg/kg, p.o.) decreases the growth of malignant cells in both mouse mammary tumor virus-driven polyomavirus middle T antigen (MMTV-PyMT) model of mammary carcinogenesis and keratin 14-expressing human papillomavirus type 16 (K14-HPV-16) transgenic model of cervical carcinogenesis.
Kidney Int. 2023 Jul;104(1):108-123.
Single cell landscape of parietal epithelial cells in healthy and diseased states
BLZ945 (Sotuletinib) purchased from AbMole
Res Sq. 2023 Jun 6;rs.3.rs-2972427.
CAR T-cell design dependent remodeling of the brain tumor immune microenvironment identify macrophages as key players that inhibit or promote anti-tumor activity
BLZ945 (Sotuletinib) purchased from AbMole
Patent. CN115381817B 2023 Sep 05.
Patent. CN115381817B
BLZ945 (Sotuletinib) purchased from AbMole
Patent. CN115381817A 2023-09-05.
Patent. CN115381817A
BLZ945 (Sotuletinib) purchased from AbMole
Patent. CN115381817A 2023 Sep 05; .
Patent. CN115381817A
BLZ945 (Sotuletinib) purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | TGCT cell |
| Preparation method | TGCT cell pellets treated with sotuletinib at concentrations 0, 50, 250, and 500 µM for 96 h were subjected to check the expression of BAX and BCL‑2 by Western blot analysis. |
| Concentrations | 0, 50, 250, and 500 µM |
| Incubation time | 96 h |
| Animal Experiment | |
|---|---|
| Animal models | Female Balb/c SCID and C57BL/6 mice |
| Formulation | 20% (v/v) 1,3-cyclodextrin |
| Dosages | 100 mg/kg |
| Administration | Oral |
| Molecular Weight | 398.48 |
| Formula | C20H22N4O3S |
| CAS Number | 953769-46-5 |
| Solubility (25°C) | DMSO 69 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related CSF-1R (c-Fms) Products |
|---|
| GW2580
GW2580 is a selective CSF-1R inhibitor for c-FMS with IC50 of 30 nM, 150- to 500-fold selective compared to b-Raf, CDK4, c-KIT, c-SRC, EGFR, ERBB2/4, ERK2, FLT-3, GSK3, ITK, JAK2 etc. |
| PLX647
PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC50 of 28/16 nM respectively. |
| Ki 20227
Ki 20227 is a c-Fms inhibitor; suppresses osteolysis and osteoclast accumulation. |
| PLX5622
PLX5622 is a highly selective brain penetrant and oral active CSF1R inhibitor with an Ki of 5.9 nM. |
| cFMS Receptor Inhibitor II
cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
